Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier LabfiledCriticalServier Lab
Priority to UY28969ApriorityCriticalpatent/UY28969A1/en
Publication of UY28969A1publicationCriticalpatent/UY28969A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proporciona forma cristalina alfa del ranelato de estroncio de fórmula (I) Caracterizada por su diagrama de difracción de rayos X de polvo y por un contenido de agua de 22 a 24%. MedicamentosAlpha crystalline form of the strontium ranelate of formula (I) is provided, characterized by its powder X-ray diffraction diagram and a water content of 22 to 24%. Medicines
UY28969A2005-06-172005-06-17
ALFA CRYSTAL FORM OF THE STRONTIUM RANELATE, PROCEDURE FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
UY28969A1
(en)
CRYSTAL FORMS OF 2-TIAZOLIL-4-QUINOLIL-OXI AMIDAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF HCV INFECTION.
CRYSTALLINE POLYMORPH OF 3 - {[5- (AZETIDIN-1-ILCARBONIL) PIRAZIN-2-IL] OXI} -5 - {[(1S) -1-METHYL-2- (METILOXI) ETIL] OXI} -N- ( 5-METHYLPIRAZIN-2-IL) BENZAMIDE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESS TO PREPARE IT AND USE OF THE SAME FOR THE TREATMENT OF TYPE II DIABETES AND / OR OBESITY.
HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-4,5, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT OR MODULATE NITRIC ACID SYNTHESIS